National Institute of Allergy & Infectious Diseases: Monoclonal Antibody Prevents Malaria Infection In African Adults
November 01, 2022
November 01, 2022
WASHINGTON, Nov. 1 (TNSjou) -- The U.S. Department of Health and Human Services' National Institute of Allergy and Infectious Diseases issued the following news release on Oct. 31, 2022:
One dose of an antibody drug safely protected healthy, non-pregnant adults from malaria infection during an intense six-month malaria season in Mali, Africa, a National Institutes of Health clinical trial has found. The antibody was up to 88.2% effective at preventing infection over a 24-week p . . .
One dose of an antibody drug safely protected healthy, non-pregnant adults from malaria infection during an intense six-month malaria season in Mali, Africa, a National Institutes of Health clinical trial has found. The antibody was up to 88.2% effective at preventing infection over a 24-week p . . .